Bolt Biotherapeutics, Inc.NASDAQ: BOLT

Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

· Issued by Bolt Biotherapeutics, Inc. via GlobeNewswire

Summary by 6ix AI

Bolt Biotherapeutics, a clinical-stage biotech developing antibodies that act on more than one target, had a loss from operations of $4.7 million for the third quarter ended September 30, 2026, compared with $7.7 million a year earlier. In October 2026, it completed its acquisition of Prana Therapies and a concurrent $120 million private placement.

Key details

  • Collaboration revenue was zero for the quarter, versus $2.2 million a year earlier. Research and development expenses were $2.2 million versus $6.5 million, mainly due to an R&D tax incentive, lower salary costs from restructuring and less research activity. General and administrative expenses were $2.5 million versus $3.3 million.
  • Bolt acquired Prana on October 23, 2026 in a stock-for-stock reverse merger, issuing 430,746 common shares and 16,360.929 shares of Series D non-voting preferred stock, each preferred share convertible into 1,000 common shares. Sheila Gujrathi, M.D., Prana co-founder and former CEO, became Bolt's Chief Strategy Officer and joined its board.
  • In the private placement, Bolt sold 13,995.311 shares of Series D Preferred Stock with warrants for gross proceeds of $120.0 million, before placement agent fees and other offering expenses and not including any proceeds from exercise of the warrants.
  • Prana's pipeline is now Bolt's main development focus. Its lead drug, PRA-216, an antibody blocking two inflammation-related targets (IL-4Rα and TSLP), has started mid-stage (Phase 2) studies in asthma, atopic dermatitis and chronic obstructive pulmonary disease, with a fourth Phase 2 study planned in eosinophilic esophagitis.
  • Following the Prana acquisition, the Chesapeake Master Lease was terminated, with an effective lease expiration date of January 1, 2027.

What’s still pending

  • Bolt will call stockholder meetings as soon as practicable to approve conversion of the Series D Preferred Stock into common stock and other matters in the merger agreement.
  • Subject to that approval, Bolt expects about 34.2 million common shares outstanding on an as-converted basis, before exercise of the private placement warrants.
  • Bolt expects initial PRA-216 Phase 2 data beginning in the second quarter of 2027, and expects a second wholly owned program from its INSPIRE antibody platform to enter the clinic and generate initial clinical data in the second half of 2027.
  • Bolt expects the financing to fund operations into 2028.

6ix AI wrote this summary from the release below and checked it against the release.

  • Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary development focus
  • Initiated Phase 2 studies with PRA-216, a half-life-extended IL-4Rα/TSLP bispecific, in asthma, atopic dermatitis and chronic obstructive pulmonary disease with initial data expected in 2Q 2027
  • Recently disclosed PRA-216 Phase 1 data provided first clinical validation of PRA-216 and the proprietary INSPIRE multispecific antibody platform with the potential for at-home maintenance dosing every 8 to 12 weeks; a second wholly owned INSPIRE program is expected to enter the clinic and generate initial clinical data in 2H 2027
  • Cash runway expected to fund operations into 2028 through multiple clinical and preclinical milestones

REDWOOD CITY, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company advancing next-generation, half-life-extended multispecific antibodies, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

In October, Bolt completed its acquisition of Prana Therapies in a sign-and-close, stock-for-stock reverse merger and closed a concurrent $120 million private placement financing with leading healthcare institutional investors. Following the transaction, Prana’s pipeline became the primary development focus of the company, led by flagship program PRA-216, an IL-4Rα/TSLP bispecific antibody in Phase 2 development across multiple high-value inflammatory indications. In connection with the transaction, Sheila Gujrathi, M.D., Co-Founder and former Chief Executive Officer of Prana, was appointed Chief Strategy Officer of Bolt and joined the company’s Board of Directors.

“The transaction and financing provide us with the capital and public-company foundation to advance PRA-216 and the broader INSPIRE pipeline through what we believe will be an exciting and highly data-rich period ahead,” said Sheila Gujrathi, M.D., Chief Strategy Officer of Bolt Biotherapeutics. “PRA-216 is our flagship program and the first clinical validation of the INSPIRE platform. It is now in Phase 2 development in asthma, COPD and atopic dermatitis, with an additional study planned in eosinophilic esophagitis, and we expect patient proof-of-concept data across all four studies beginning in the second quarter of 2027. These studies will evaluate the potential of PRA-216 to move beyond the efficacy ceiling of single-mechanism therapies by combining complementary IL-4Rα and TSLP inhibition, while offering the potential convenience of infrequent, at-home dosing. Beyond PRA-216, we look forward to advancing additional wholly owned programs from INSPIRE as we work to build a new generation of differentiated multispecific therapies.”

“Completing the Prana acquisition marks an important transformation for Bolt,” said Willie Quinn, President and Chief Executive Officer of Bolt Biotherapeutics. “With a strong balance sheet, an advanced clinical program and a differentiated platform, we believe we are well positioned to execute against the important milestones ahead.”

Third Quarter 2026 Financial Results

  • Cash and Financing– In October 2026, subsequent to the end of the third quarter, Bolt completed a private placement financing resulting in approximately $120 million in gross proceeds. The financing is expected to fund the company’s operations into 2028 and through multiple anticipated clinical and preclinical milestones.
  • Collaboration Revenue – Total collaboration revenue was zero for the quarter ended September 30, 2026, compared to $2.2 million for the same quarter in 2025. Revenue in the comparative periods was generated from services performed under the R&D collaborations as we fulfill our performance obligations.
  • Research and Development (R&D) Expenses – R&D expenses were $2.2 million for the quarter ended September 30, 2026, compared to $6.5 million for the same quarter in 2025. The decrease between the comparable periods was mainly due to a R&D tax incentive, a decrease in salary and related expenses primarily as a result of our restructuring, and overall lower research and development activities.
  • General and Administrative (G&A) Expenses – G&A expenses were $2.5 million for the quarter ended September 30, 2026, compared to $3.3 million for the same quarter in 2025. The decrease between the comparable periods was mainly due to a decrease in salary and related expenses primarily as a result of our restructuring as well as lower personnel expenses.
  • Loss from Operations – Loss from operations was $4.7 million for the quarter ended September 30, 2026, compared to $7.7 million for the same quarter in 2025.

Subsequent Events

  • Merger with Prana Therapies: Bolt acquired Prana on October 23, 2026 through the issuance of 430,746 shares of common stock and 16,360.929 shares of Series D non-voting preferred stock, each share of which is convertible into 1,000 shares of Common Stock. Bolt will call and hold stockholders’ meetings as soon as practicable to approve the conversion of the Series D Preferred Stock into Common Stock, and other matters as specified in the Merger Agreement. Bolt will provide the disclosures required by ASC 805, Business Combinations, once they are ready and no later than January 8, 2027.
  • Private Placement: Concurrent with the acquisition of Prana, Bolt sold and issued 13,995.311 shares of Series D Preferred Stock and accompanying warrants for aggregate gross proceeds of $120.0 million (not including any cash proceeds that may be received upon the exercise of such warrants), before deducting placement agent fees and other offering expenses.
  • Shares Outstanding: After the acquisition of Prana and the Private Placement, subject to stockholder approval of the conversion of the Series D non-voting convertible preferred stock, Bolt is expected to have approximately 34.2 million shares of common stock outstanding on an as-converted basis, before giving effect to the exercise of the PIPE warrants
  • Lease Termination: Following the October 2026 acquisition of Prana, the Chesapeake Master Lease has been terminated with an effective lease expiration date of January 1, 2027.

About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Through the proprietary INSPIRE platform it acquired from Prana Therapies, the company combines complementary therapeutic mechanisms in fully IgG-based molecules designed for differentiated efficacy, extended exposure, and convenient dosing.

The company’s lead program, PRA-216, is a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease, and atopic dermatitis, with a fourth Phase 2 study planned in eosinophilic esophagitis. In addition to PRA-216, Bolt Biotherapeutics is advancing a wholly owned pipeline of additional INSPIRE-based multispecific programs across diseases with significant unmet need.

Bolt’s pipeline also includes BDC-4182, a claudin 18.2-targeting Boltbody™ ISAC.

For more information, please visit https://www.boltbio.com/.

Forward-Looking Statements
This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including, without limitation, statements regarding Bolt, Prana, the concurrent private placement financing and the acquisition of Prana by Bolt (the “Transactions”) and other matters, including, without limitation, statements regarding: the Transactions, including any additional gross proceeds that may be received upon exercise, if any, of accompanying warrants, if any, and the expected effects, perceived benefits or opportunities and related timing with respect thereto; expectations regarding or plans for the company’s pipeline, including its ongoing and planned clinical trials, research and development programs and the expected timing for key milestones, including the release of clinical data; the potential benefits of PRA-216 and Prana’s other clinical programs; and expectations regarding the use of proceeds from the concurrent private placement financing and cash runway expectations therefrom, including such proceeds funding the company through key clinical milestones; and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “on track,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would,” or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our current beliefs, estimates and assumptions only as of the date of this press release and information contained in this press release should not be relied upon as representing our estimates as of any subsequent date. These statements, and related risks, uncertainties, factors and assumptions, include, but are not limited to: the company’s ability to realize the anticipated benefits from the transactions, including as a result of its failure to receive the requisite stockholder approvals; investors in the private placement may not exercise their warrants and the company may not receive any additional proceeds therefrom; the potential product candidates that we develop may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; such product candidates may not be beneficial to patients or become commercialized; and our ability to maintain our current collaborations and establish further collaborations. These risks are not exhaustive. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. These filings, when available, are available on the investor relations section of our website at investors.boltbio.com and on the SEC’s website at www.sec.gov.

Contacts:    
Christina Trout
VP, Corporate Development
(650) 665-9295
[email protected]

Matthew DeYoung
Argot Partners
(212) 600-1902
[email protected]

BOLT BIOTHERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited, in thousands, except share and per share amounts)
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Collaboration revenue$—$2,169$31$5,195
Operating expenses:
Research and development2,2096,53512,18723,545
General and administrative2,5213,3377,74110,678
Impairment charges——808—
Total operating expense4,7309,87220,73634,223
Loss from operations(4,730)(7,703)(20,705)(29,028)
Other income (expense), net:
Interest income, net1454775992,129
Other income, net16382557154
Total other income (expense), net3085591,1562,283
Net loss(4,422)(7,144)(19,549)(26,745)
Net unrealized gain (loss) on marketable securities1(4)(22)(107)
Comprehensive loss$(4,421)$(7,148)$(19,571)$(26,852)
Net loss per share, basic and diluted$(2.25)$(3.72)$(10.09)$(13.94)
Weighted-average shares outstanding, basic and diluted1,966,0841,919,4411,936,9541,918,014
BOLT BIOTHERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands)
September 30,December 31,
20262025
Assets
Current assets:
Cash and cash equivalents$13,782$11,703
Short-term investments1,01615,802
Restricted cash200200
Prepaid expenses and other current assets2,0822,555
Total current assets17,08030,260
Property and equipment, net3411,245
Operating lease right-of-use assets16,36719,230
Restricted cash, non-current1,5381,538
Long-term investments2474,337
Other assets18138
Total assets$35,591$56,748
Liabilities and stockholders' equity
Current liabilities:
Accounts payable$633$1,443
Accrued expenses and other current liabilities3,3853,717
Deferred revenue1,066449
Operating lease liabilities3,2312,826
Total current liabilities8,3158,435
Operating lease liabilities, net of current portion17,65820,132
Deferred revenue, non-current9241,544
Other long-term liabilities132132
Total liabilities27,02930,243
Commitments and contingencies
Stockholders' equity:
Common stock——
Additional paid-in capital488,933487,305
Accumulated other comprehensive loss(43)(21)
Accumulated deficit(480,328)(460,779)
Total stockholders' equity8,56226,505
Total liabilities and stockholders' equity$35,591$56,748
BOLT BIOTHERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
Nine Months Ended September 30,
20262025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss$(19,549)$(26,745)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization4401,036
Stock-based compensation expense1,6031,741
Accretion of discount on marketable securities(132)(509)
Gain on sale of property and equipment(245)(288)
Asset impairment808—
Non-cash lease expense2,0551,875
Changes in operating assets and liabilities:
Prepaid expenses and other assets593(322)
Accounts payable and accrued expenses(1,142)(5,233)
Operating lease liabilities(2,069)(1,620)
Deferred revenue(3)(2,762)
Other long-term liabilities—133
Net cash used in operating activities(17,641)(32,694)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment(13)(72)
Proceeds from sales of property and equipment722963
Purchases of marketable securities(1,230)(17,176)
Maturities of marketable securities20,21659,513
Net cash provided by investing activities19,69543,228
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock2514
Net cash provided by financing activities2514
NET INCREASE IN CASH2,07910,548
Cash, cash equivalents and restricted cash at beginning of year13,4418,970
Cash, cash equivalents and restricted cash at end of period$15,520$19,518
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents$13,782$17,753
Restricted cash1,7381,765
Total cash, cash equivalents and restricted cash$15,520$19,518

View original source (GlobeNewswire)Bolt Biotherapeutics, Inc. on 6ix

Story so far

Earlier from Bolt Biotherapeutics

All Bolt Biotherapeutics news releases